Hypoxia-inducible factors enhance glutamate signaling in cancer cells

Oncotarget

Volumn 5, Issue 19, 2014, Pages 8853-8868

  Hu, Hongxia ^a   Takano, Naoharu ^a   Xiang, Lisha ^a,b   Gilkes, Daniele M ^a   Luo, Weibo ^a   Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

AMPA receptor; Clear cell renal carcinoma; Hepatocellular carcinoma; HIF 1

Indexed keywords

GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; HYPOXIA INDUCIBLE FACTOR; TRANSCRIPTION FACTOR; AMPA RECEPTOR; ARNT PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 3; FYN PROTEIN, HUMAN; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 2; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 3; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; PROTEIN KINASE FYN; SLC1A1 PROTEIN, HUMAN; SLC1A3 PROTEIN, HUMAN; SMALL INTERFERING RNA; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLEAR CELL CARCINOMA; GENE; GENETIC CODE; GRIA2 GENE; GRIA3 GENE; HUMAN; HUMAN CELL; HYPOXIA; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; RECEPTOR BINDING; SLC1A1 GENE; SLC1A3 GENE; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL HYPOXIA; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; KIDNEY CARCINOMA; KIDNEY TUMOR; LIVER TUMOR; MALE; METABOLISM; MOUSE; RNA INTERFERENCE; SCID MOUSE; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMIC ACID; HEK293 CELLS; HETEROGRAFTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-FYN; RECEPTORS, AMPA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84910077247     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2593     Document Type: Article

References (66)

1. Wang GL, Jiang BH, Rue EA and Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92(12):5510-5514.
2. Keith B, Johnson RS and Simon MC. HIF-1a and HIF-2a: sibling rivalry in hypoxic tumor growth and progression. Nat Rev Cancer. 2012; 12(1):9-22.
3. Prabhakar NR and Semenza GL. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev. 2012; 92(3):967-1003.
4. Kaelin WG, Jr. and Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008; 30(4):393-402.
5. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012; 148(3):399-408.
6. Dunwoodie SL. The role of hypoxia in development of the Mammalian embryo. Dev Cell. 2009; 17(6):755-773.
7. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010; 29(5):625-634.
8. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1):38-47.
9. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-732.
10. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 499(7456):43-49.
11. Nedergaard M, Takano T and Hansen AJ. Beyond the role of glutamate as a neurotransmitter. Nat Rev Neurosci. 2002; 3(9):748-755.
12. Ye ZC and Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 1999; 59(17):4383-4391.
13. Takano T, Lin JH, Arcuino G, Gao Q, Yang J and Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med. 2001; 7(9):1010-1015.
14. Rzeski W, Turski L and Ikonomidou C. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A. 2001; 98(11):6372-6377.
15. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr. 2000; 130(4S Suppl):1007S-1015S.
16. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, Zhu H, Robbins C, Makalowska I, Shin SS, Marin Y, Roberts KG, Yudt LM, Chen A, Cheng J, Incao A, Pinkett HW, Graham CL, Dunn K, Crespo-Carbone SM, Mackason KR, Ryan KB, Sinsimer D, Goydos J, Reuhl KR, Eckhaus M, Meltzer PS, Pavan WJ, Trent JM and Chen S. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet. 2003; 34(1):108-112.
17. Choi KY, Chang K, Pickel JM, Badger JD 2nd and Roche KW. Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice. Proc Natl Acad Sci U S A. 2011; 108(37):15219-15224.
18. Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Sifringer M, Rzeski W, Staufner C, Brocke KS, Turski L and Ikonomidou C. Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol. 2009; 132(4):435-445.
19. Namkoong J, Shin SS, Lee HJ, Marin YE, Wall BA, Goydos JS and Chen S. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res. 2007; 67(5):2298-2305.
20. de Groot JF, Piao Y, Lu L, Fuller GN and Yung WK. Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol. 2008; 88(2):121-133.
21. Watanabe K, Kanno T, Oshima T, Miwa H, Tashiro C and Nishizaki T. The NMDA receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer cells. Biochem Biophys Res Commun. 2008; 367(2):487-490.
22. Luksch H, Uckermann O, Stepulak A, Hendruschk S, Marzahn J, Bastian S, Staufner C, Temme A and Ikonomidou C. Silencing of selected glutamate receptor subunits modulates cancer growth. Anticancer Res. 2011; 31(10):3181-3192.
23. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M and Seshagiri S. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010; 466(7308):869-873.
24. Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH and Samuels Y. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet. 2011; 43(11):1119-1126.
25. Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patino-Garcia A, Sierrasesumaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, Barkauskas DA, Marina N, de Toledo SR, Petrilli AS, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter DJ, Malats N, Kogevinas M, Wacholder S, Troisi R, Helman L, Fraumeni JF Jr, Yeager M, Hoover RN and Chanock SJ. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013; 45(7):799-803.
26. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA and Samuels Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011; 43(5):442-446.
27. Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, Shen H, Li Y, Omilian AR, Hill A, Head K, Guru K, Kunnev D, Leach R, Eng KH, Darlak C, Hoeflich C, Veeranki S, Glenn S, You M, Pruitt SC, Johnson CS and Trump DL. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A. 2014;111:E672-E681.
28. Sinclair PB, Sorour A, Martineau M, Harrison CJ, Mitchell WA, O'Neill E and Foroni L. A fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia: identification and analysis of a candidate tumor suppressor gene. Cancer Res. 2004; 64(12):4089-4098.
29. Ibragimova I, Slifker MJ, Maradeo ME, Banumathy G, Dulaimi E, Uzzo RG and Cairns P. Genome-wide promoter methylome of small renal masses. PLoS One. 2013; 8(10):e77309.
30. Wu CS, Lu YJ, Li HP, Hsueh C, Lu CY, Leu YW, Liu HP, Lin KH, Hui-Ming Huang T and Chang YS. Glutamate receptor, ionotropic, kainate 2 silencing by DNA hypermethylation possesses tumor suppressor function in gastric cancer. Int J Cancer. 2010; 126(11):2542-2552.
31. Kim MS, Chang X, Nagpal JK, Yamashita K, Baek JH, Dasgupta S, Wu G, Osada M, Woo JH, Westra WH, Trink B, Ratovitski EA, Moon C and Sidransky D. The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Oncogene. 2008; 27(14):2045-2054.
32. Kim MS, Yamashita K, Chae YK, Tokumaru Y, Chang X, Zahurak M, Osada M, Park HL, Chuang A, Califano JA and Sidransky D. A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma. Clin Cancer Res. 2007; 13(22 Pt 1):6658-6665.
33. Liu JW, Kim MS, Nagpal J, Yamashita K, Poeta L, Chang X, Lee J, Park HL, Jeronimo C, Westra WH, Mori M, Moon C, Trink B and Sidransky D. Quantitative hypermethylation of NMDAR2B in human gastric cancer. Int J Cancer. 2007; 121(9):1994-2000.
34. Tamura H, Suzuki M, Moriya Y, Hoshino H, Okamoto T, Yoshida S and Yoshino I. Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma. BMC cancer. 2011; 11:220.
35. Seidlitz EP, Sharma MK, Saikali Z, Ghert M and Singh G. Cancer cell lines release glutamate into the extracellular environment. Clin Exp Metastasis. 2009; 26(7):781-787.
36. Nishizawa Y. Glutamate release and neuronal damage in ischemia. Life Sci. 2001; 69(4):369-381.
37. Yamaguchi F, Hirata Y, Akram H, Kamitori K, Dong Y, Sui L and Tokuda M. FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801. BMC Cancer. 2013; 13:468.
38. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ and Dingledine R. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010; 62(3):405-496.
39. Hayashi T, Umemori H, Mishina M and Yamamoto T. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature. 1999; 397(6714):72-76.
40. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, Krieg A, Bedogni B, LaGory E, Weissman IL, Broome-Powell M and Giaccia AJ. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCd-driven migration. Proc Natl Acad Sci U S A. 2011; 108(5):1931-1936.
41. Goswami CP and Nakshatri H. PROGgene: gene expression based survival analysis web application for multiple cancers. J Clin Bioinforma. 2013; 3(1):22.
42. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM and Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359(19):1995-2004.
43. Joly Y, Dove ES, Knoppers BM, Bobrow M and Chalmers D. Data sharing in the post-genomic world: the experience of the International Cancer Genome Consortium (ICGC) Data Access Compliance Office (DACO). PLoS computational biology. PLoS Comput Biol. 2012; 8(7):e1002549.
44. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC and Nathanson KL. HIF-a effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008; 14(6):435-446.
45. Sharma MK, Seidlitz EP and Singh G. Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun. 2010; 391(1):91-95.
46. Grewer C, Gameiro A, Zhang Z, Tao Z, Braams S and Rauen T. Glutamate forward and reverse transport: from molecular mechanism to transporter-mediated release after ischemia. IUBMB Life. 2008; 60(9):609-619.
47. Lo M, Wang YZ and Gout PW. The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008; 215(3):593-602.
48. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F and Gray JW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013; 24(4):450-465.
49. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M and Wada K. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science. 1997; 276(5319):1699-1702.
50. Zschocke J, Allritz C, Engele J and Rein T. DNA methylation dependent silencing of the human glutamate transporter EAAT2 gene in glial cells. Glia. 2007; 55(7):663-674.
51. Piao Y, Lu L and de Groot J. AMPA receptors promote perivascular glioma invasion via β1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol. 2009; 11(3):260-273.
52. Ripka S, Riedel J, Neesse A, Griesmann H, Buchholz M, Ellenrieder V, Moeller F, Barth P, Gress TM and Michl P. Glutamate receptor GRIA3-target of CUX1 and mediator of tumor progression in pancreatic cancer. Neoplasia. 2010; 12(8):659-667.
53. Bennett LB, Schnabel JL, Kelchen JM, Taylor KH, Guo J, Arthur GL, Papageorgio CN, Shi H and Caldwell CW. DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma. Genes Chromosomes Cancer. 2009; 48(9):828-841.
54. Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M, Lahrmann B, Grabe N, Flechtenmacher C, Schmidt CR, Seiwert T, Dyckhoff G, Dietz A, Höfler D, Pawlita M, Benner A, Bosch FX, Plinkert P, Plass C, Weichenhan D and Hess J. HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Invest. 2013; 123(6):2488-2501.
55. Tsibris JC, Maas S, Segars JH, Nicosia SV, Enkemann SA, O'Brien WF and Spellacy WN. New potential regulators of uterine leiomyomata from DNA arrays: the ionotropic glutamate receptor GluR2. Biochem Biophys Res Commun. 2003; 312(1):249-254.
56. Arslan AA, Gold LI, Mittal K, Suen TC, Belitskaya-Levy I, Tang MS and Toniolo P. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod. 2005; 20(4):852-863.
57. Leja J, Essaghir A, Essand M, Wester K, Oberg K, Totterman TH, Lloyd R, Vasmatzis G, Demoulin JB and Giandomenico V. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol. 2009; 22(2):261-272.
58. Beretta F, Bassani S, Binda E, Verpelli C, Bello L, Galli R and Passafaro M. The GluR2 subunit inhibits proliferation by inactivating Src-MAPK signalling and induces apoptosis by means of caspase 3/6-dependent activation in glioma cells. Eur J Neurosci. 2009; 30(1):25-34.
59. Herner A, Sauliunaite D, Michalski CW, Erkan M, De Oliveira T, Abiatari I, Kong B, Esposito I, Friess H and Kleeff J. Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Int J Cancer. 2011; 129(10):2349-2359.
60. Li L and Hanahan D. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell. 2013; 153(1):86-100.
61. Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS and Fine HA. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer. 2010; 116(7):1776-1782.
62. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO and Semenza GL. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proc Natl Acad Sci U S A. 2008; 105(50):19579-19586.
63. Chintala S, Najrana T, Toth K, Cao S, Durrani FA, Pili R and Rustum YM. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. BMC Cancer. 2012; 12:293.
64. Xiang L, Gilkes DM, Chaturvedi P, Luo W, Hu H, Takano N, Liang H and Semenza GL. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. J Mol Med (Berl). 2014; 92:151-164.
65. Onnis B, Rapisarda A and Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med. 2009; 13(9A):2780-2786.
66. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV and Semenza GL. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell. 2007; 11(5):407-420.